330 related articles for article (PubMed ID: 10083506)
1. Mycophenolate mofetil in living donor renal allograft recipients.
Park K; Moon JI; Kim SI; Kim YS
Transplant Proc; 1999; 31(1-2):1133. PubMed ID: 10083506
[No Abstract] [Full Text] [Related]
2. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
Park K; Kim SI; Moon JI; Kim YS; Kim MS
Transplant Proc; 1998 Nov; 30(7):3575. PubMed ID: 9838565
[No Abstract] [Full Text] [Related]
3. Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.
Remport A; Sasvári I; Toronyi E; Borka P; Lázár N; Járay J; Perner F
Transplant Proc; 2001 May; 33(3):2302-3. PubMed ID: 11377537
[No Abstract] [Full Text] [Related]
4. Mycophenolate mofetil (Cellcept) in renal transplantation: the European experience. The European Mycophenolate Mofetil Co-operative Study Group.
Carl S; Wiesel M
Transplant Proc; 1997 Nov; 29(7):2932-5. PubMed ID: 9365619
[No Abstract] [Full Text] [Related]
5. Comparison of two corticosteroid regimens in combination with CellCept and cyclosporine A for prevention of acute allograft rejection: 12 month results of a double-blind, randomized, multi-center study. M 55002 Study Group.
Lebranchu Y
Transplant Proc; 1999; 31(1-2):249-50. PubMed ID: 10083095
[No Abstract] [Full Text] [Related]
6. Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation.
Kim HC; Park SB; Kim HT; Cho WH; Park CH
Transplant Proc; 2000 Nov; 32(7):1751-2. PubMed ID: 11119919
[No Abstract] [Full Text] [Related]
7. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
[No Abstract] [Full Text] [Related]
8. Preoperative induction therapy with oral cyclosporine for recipients of living-related renal transplants.
Rudich SM; Bhaduri S; Chang T; Cahn J; Katznelson S; Perez RV
Transplant Proc; 1998 Jun; 30(4):1339-42. PubMed ID: 9636545
[No Abstract] [Full Text] [Related]
9. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate Mofetil Acute Renal Rejection Study Group
Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil/Neoral/steroid vs Neoral/steroid therapy for prophylaxis of acute rejection in renal transplant recipients.
Carmellini M; Vistoli F; Bellini R; Boggi U; Rindi P; Rizzo G; Mosca F
Transplant Proc; 1999; 31(1-2):1162-4. PubMed ID: 10083519
[No Abstract] [Full Text] [Related]
11. Treatment with mycophenolate mofetil in kidney transplant patients with organs from donors aged over 60 years: one-year monitoring results.
Agraz I; Guirado L; Andrade M; Olaya M; Vila A; Solá R
Transplant Proc; 1999 Sep; 31(6):2272-4. PubMed ID: 10500573
[No Abstract] [Full Text] [Related]
12. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection.
Behrend M; Lueck R; Pichlmayr R
Transplant Proc; 1997 Nov; 29(7):2927-9. PubMed ID: 9365617
[No Abstract] [Full Text] [Related]
13. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
Forsythe J
Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
[No Abstract] [Full Text] [Related]
14. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis.
Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM
Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570
[No Abstract] [Full Text] [Related]
15. Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 de Octubre, Madrid.
Morales JM; Andrés A; Morales E; Herrero JC; Cubas A; Praga M; Hernández E; Ortuño T; Dominguez-Gil B; Carreño A; Delgado M; Manzanares C
Transplant Proc; 1999 Nov; 31(7A):75S-77S. PubMed ID: 10576051
[No Abstract] [Full Text] [Related]
16. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
[No Abstract] [Full Text] [Related]
17. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
[No Abstract] [Full Text] [Related]
18. Transplantation without maintenance corticosteroids in 1-haplotype and 2-haplotype HLA matched living-related renal transplant recipients treated with mycophenolate mofetil and cyclosporine.
Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
Transplant Proc; 1999; 31(1-2):744-5. PubMed ID: 10083317
[No Abstract] [Full Text] [Related]
19. Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation.
Crespo JF; Górriz JL; Sancho A; Avila A; Alcoy E; Pallardó LM
Transplant Proc; 1999 Sep; 31(6):2261-2. PubMed ID: 10500568
[No Abstract] [Full Text] [Related]
20. A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients.
Sells RA; Bakran A; Brown MW; Grinyo J; Hammad A; Hyatt D; Owens G
Transplant Proc; 1998 Dec; 30(8):4098. PubMed ID: 9865311
[No Abstract] [Full Text] [Related]
[Next] [New Search]
